Compare ZDGE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | IMMX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 306.2M |
| IPO Year | N/A | 2021 |
| Metric | ZDGE | IMMX |
|---|---|---|
| Price | $3.51 | $5.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.4M |
| Earning Date | 12-12-2025 | 11-07-2025 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,814,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.73 | $1.34 |
| 52 Week High | $4.89 | $7.73 |
| Indicator | ZDGE | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 56.94 |
| Support Level | $2.72 | $5.46 |
| Resistance Level | $3.83 | $6.09 |
| Average True Range (ATR) | 0.41 | 0.74 |
| MACD | 0.13 | -0.12 |
| Stochastic Oscillator | 51.25 | 38.39 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.